Dongwei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongwei Zhang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Xiaoyan Liao
Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA
10 shared publicationsJingmei Lin
Department of Pathology and Laboratory Medicine, Wake Forest University, Winston-Salem, NC
2 shared publicationsJinping Lai
Department of Pathology and Laboratory of Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, USA
2 shared publicationsLindsay Alpert
Department of Pathology, University of Chicago, Chicago, IL, USA
2 shared publicationsShaomin Hu
Department of Pathology, Cleveland Clinic, Cleveland, OH, USA
2 shared publications- Xiaoyan Liao
University of Rochester Medical Center
2 shared publications
Latest Publications
- 18 August 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
Endolymphatic Sac Tumors With Aberrant Immunophenotypes
Endolymphatic sac tumor (ELST) is a rare, locally destructive, but non-metastasizing neoplasm arising from the intraosseous epithelium of the endolymphatic duct and sac. Morphologically and immunohistochemically, ELST overlaps with metastatic renal cell carcinoma (RCC), and both neoplasms occur with increased frequency in patients with von Hippel–Lindau (VHL) disease. The largest study to date comparing the immunophenotypes of ELST and RCC found that 100% of ELSTs (25/25) were positive for CA9, whereas all tested ELSTs were negative for CD10 (0/16) and RCC (0/15). They concluded that strong expressions of PAX8 and CA9 and negative expressions of CD10 and RCC are helpful in discriminating between metastatic RCC and ELST. We present two ELSTs that defy this postulate and expand the immunophenotypic profile of these tumors. The first ELST occurred in a 66-year-old woman and was positive for PAX8, CA9, and RCC, and negative for CD10. The second ELST occurred in a 61-year-old man and was positive for PAX8 but negative for CA9. No VHL mutation was identified by whole exome sequencing in the latter tumor. Both patients had no history of RCC and no detectable renal mass on imaging at diagnosis and on follow-up. Our findings indicate that recommended immunohistochemical panels for distinguishing ELST from metastatic RCC are not reliable, underscoring the importance of integrating clinical history and radiologic findings to differentiate tumors with overlapping genetics, histology, and immunophenotype for appropriate patient management.
- 18 August 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
Endolymphatic Sac Tumors With Aberrant Immunophenotypes
Endolymphatic sac tumor (ELST) is a rare, locally destructive, but non-metastasizing neoplasm arising from the intraosseous epithelium of the endolymphatic duct and sac. Morphologically and immunohistochemically, ELST overlaps with metastatic renal cell carcinoma (RCC), and both neoplasms occur with increased frequency in patients with von Hippel–Lindau (VHL) disease. The largest study to date comparing the immunophenotypes of ELST and RCC found that 100% of ELSTs (25/25) were positive for CA9, whereas all tested ELSTs were negative for CD10 (0/16) and RCC (0/15). They concluded that strong expressions of PAX8 and CA9 and negative expressions of CD10 and RCC are helpful in discriminating between metastatic RCC and ELST. We present two ELSTs that defy this postulate and expand the immunophenotypic profile of these tumors. The first ELST occurred in a 66-year-old woman and was positive for PAX8, CA9, and RCC, and negative for CD10. The second ELST occurred in a 61-year-old man and was positive for PAX8 but negative for CA9. No VHL mutation was identified by whole exome sequencing in the latter tumor. Both patients had no history of RCC and no detectable renal mass on imaging at diagnosis and on follow-up. Our findings indicate that recommended immunohistochemical panels for distinguishing ELST from metastatic RCC are not reliable, underscoring the importance of integrating clinical history and radiologic findings to differentiate tumors with overlapping genetics, histology, and immunophenotype for appropriate patient management.
- 21 January 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (3) , 376-387
Perihilar Intraductal Papillary Neoplasm of the Bile Ducts
The College of American Pathologists recognizes “intraductal papillary neoplasm of the bile ducts (IPNB) with an associated invasive carcinoma” in its protocols for the pancreas and intrahepatic bile ducts, but not for the perihilar or distal bile ducts. We aimed to investigate the clinicopathologic and molecular features of 27 surgically resected perihilar IPNB cases. The cohort included 14 males and 13 females, with a median age of 70 years. Six IPNBs were noninvasive, while 21 had associated invasive carcinoma. The median overall tumor size was 2.8 cm, and the median invasive tumor size was 1.2 cm. Eight of 16 patients had elevated CA19-9. Immunohistochemistry as a surrogate of molecular analysis was performed in 19 cases with invasive carcinoma. Among them, positive PD-L1 expression was found in 3 cases (15.8%, all had low expression, CPS<5). DNA mismatch repair deficiency (loss of MSH2 and MSH6) and p53 overexpression were each identified in 1 case (5.3%). All cases were negative for HER2 and pan-TRK. After a median follow-up of 38 months, 11 patients died of disease. Next-generation sequencing revealed genetic alterations impacting multiple signaling pathways, including MAPK/ERK, WNT/β-catenin, TGF-β, DNA damage response, and PI3K/AKT. Our case series suggests that IPNB with associated invasive carcinoma may be included in CAP protocols as one of the carcinoma types of perihilar bile ducts. Future studies are warranted to compare perihilar IPNB with those originating in other biliary tract sites. We expect our molecular findings to help guide the selection of potential therapeutic targets.
- 21 January 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (3) , 376-387
Perihilar Intraductal Papillary Neoplasm of the Bile Ducts
The College of American Pathologists recognizes “intraductal papillary neoplasm of the bile ducts (IPNB) with an associated invasive carcinoma” in its protocols for the pancreas and intrahepatic bile ducts, but not for the perihilar or distal bile ducts. We aimed to investigate the clinicopathologic and molecular features of 27 surgically resected perihilar IPNB cases. The cohort included 14 males and 13 females, with a median age of 70 years. Six IPNBs were noninvasive, while 21 had associated invasive carcinoma. The median overall tumor size was 2.8 cm, and the median invasive tumor size was 1.2 cm. Eight of 16 patients had elevated CA19-9. Immunohistochemistry as a surrogate of molecular analysis was performed in 19 cases with invasive carcinoma. Among them, positive PD-L1 expression was found in 3 cases (15.8%, all had low expression, CPS<5). DNA mismatch repair deficiency (loss of MSH2 and MSH6) and p53 overexpression were each identified in 1 case (5.3%). All cases were negative for HER2 and pan-TRK. After a median follow-up of 38 months, 11 patients died of disease. Next-generation sequencing revealed genetic alterations impacting multiple signaling pathways, including MAPK/ERK, WNT/β-catenin, TGF-β, DNA damage response, and PI3K/AKT. Our case series suggests that IPNB with associated invasive carcinoma may be included in CAP protocols as one of the carcinoma types of perihilar bile ducts. Future studies are warranted to compare perihilar IPNB with those originating in other biliary tract sites. We expect our molecular findings to help guide the selection of potential therapeutic targets.
- 5 May 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (8)
Mucocyte‐Rich/Extracellular Mucin‐Poor Salivary Duct Carcinoma: An Unusual Morphological Variant Mimicking Mucoepidermoid Carcinoma
Salivary duct carcinoma (SDC) is an aggressive malignancy of the salivary gland. The rare mucin‐rich variant is characterized by the presence of nests of malignant cells floating in pools of extracellular mucin. We present an unusual case of SDC with abundant mucocytes but complete absence of extracellular mucin, initially misdiagnosed as mucoepidermoid carcinoma (MEC) on fine needle aspiration (FNA). The patient, an 85‐year‐old woman, presented with a 3.2 cm heterogeneous, partially cystic, right parotid mass causing facial nerve paralysis. FNA revealed mixed pleomorphic and hyperchromatic epithelial cells with abundant mucocytes. The tumor cells were focally positive for p63 and androgen receptor (AR). The patient was diagnosed with intermediate‐grade MEC. Subsequent parotidectomy revealed high‐grade duct‐forming carcinoma with extensive perineural invasion, frequent mitosis, and comedonecrosis arising from a pleomorphic adenoma. This was remarkable for numerous mucocytes and the absence of extracellular mucin. Immunohistochemically, the tumor cells expressed AR, CK7, GATA3, and GCDFP‐15, confirming the diagnosis of SDC. Whole exome sequencing revealed RAD50 p.Lys973Arg and POLE p.Arg52Trp mutations, suggesting that the DNA damage repair pathway was affected. Given the potential for variability in individual marker expression, including aberrant phenotypes, such as p63‐positive SDC or AR‐positive MEC, employing a comprehensive panel of markers for accurate diagnosis is crucial. Markers such as GATA3 and GCDFP‐15 can be useful in detecting highly aggressive SDC.
- 5 May 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (8)
Mucocyte‐Rich/Extracellular Mucin‐Poor Salivary Duct Carcinoma: An Unusual Morphological Variant Mimicking Mucoepidermoid Carcinoma
Salivary duct carcinoma (SDC) is an aggressive malignancy of the salivary gland. The rare mucin‐rich variant is characterized by the presence of nests of malignant cells floating in pools of extracellular mucin. We present an unusual case of SDC with abundant mucocytes but complete absence of extracellular mucin, initially misdiagnosed as mucoepidermoid carcinoma (MEC) on fine needle aspiration (FNA). The patient, an 85‐year‐old woman, presented with a 3.2 cm heterogeneous, partially cystic, right parotid mass causing facial nerve paralysis. FNA revealed mixed pleomorphic and hyperchromatic epithelial cells with abundant mucocytes. The tumor cells were focally positive for p63 and androgen receptor (AR). The patient was diagnosed with intermediate‐grade MEC. Subsequent parotidectomy revealed high‐grade duct‐forming carcinoma with extensive perineural invasion, frequent mitosis, and comedonecrosis arising from a pleomorphic adenoma. This was remarkable for numerous mucocytes and the absence of extracellular mucin. Immunohistochemically, the tumor cells expressed AR, CK7, GATA3, and GCDFP‐15, confirming the diagnosis of SDC. Whole exome sequencing revealed RAD50 p.Lys973Arg and POLE p.Arg52Trp mutations, suggesting that the DNA damage repair pathway was affected. Given the potential for variability in individual marker expression, including aberrant phenotypes, such as p63‐positive SDC or AR‐positive MEC, employing a comprehensive panel of markers for accurate diagnosis is crucial. Markers such as GATA3 and GCDFP‐15 can be useful in detecting highly aggressive SDC.
- 14 December 2024
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 75, 152428
Mass-forming isolated ischemic necrosis of the cecum mimicking malignancy: Clinicopathologic features of 11 cases
- 14 December 2024
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 75, 152428
Mass-forming isolated ischemic necrosis of the cecum mimicking malignancy: Clinicopathologic features of 11 cases
- Open Access
Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints
Despite major advances in non-small-cell lung cancer (NSCLC) treatment, the five-year survival rates for patients with non-oncogene-driven tumors remain low, necessitating combinatory approaches to improve outcomes. Our prior high-throughput RNAi screening identified Aurora kinase A (AURKA) as a potential key player in cisplatin resistance. In this study, we investigated AURKA’s role in platinum and radiation sensitivity in multiple NSCLC cell lines and xenograft mouse models, as well as its effect on immune checkpoints, including PD-L1, B7x, B7-H3, and HHLA2. Of 94 NSCLC patient tumor specimens, 91.5% tested positive for AURKA expression, with 34% showing moderate-to-high levels. AURKA expression was upregulated following cisplatin treatment in NSCLC cell lines PC9 and A549. Both AURKA inhibition by alisertib and inducible AURKA knockdown potentiated the cytotoxic effects of cisplatin and radiation, leading to tumor regression in doxycycline-inducible xenograft mice. Co-treated cells exhibited increased DNA double-strand breaks, apoptosis, and senescence. Additionally, AURKA inhibition alone by alisertib increased PD-L1 and B7-H3 expression. In conclusion, our study demonstrates that AURKA inhibition enhances the efficacy of platinum-based chemotherapy in NSCLC cells and modulates the expression of multiple immune checkpoints. Therefore, combinatory regimens with AURKA inhibitors should be strategically designed and further studied within the evolving landscape of chemo-immunotherapy.
Open AccessAurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints
Despite major advances in non-small-cell lung cancer (NSCLC) treatment, the five-year survival rates for patients with non-oncogene-driven tumors remain low, necessitating combinatory approaches to improve outcomes. Our prior high-throughput RNAi screening identified Aurora kinase A (AURKA) as a potential key player in cisplatin resistance. In this study, we investigated AURKA’s role in platinum and radiation sensitivity in multiple NSCLC cell lines and xenograft mouse models, as well as its effect on immune checkpoints, including PD-L1, B7x, B7-H3, and HHLA2. Of 94 NSCLC patient tumor specimens, 91.5% tested positive for AURKA expression, with 34% showing moderate-to-high levels. AURKA expression was upregulated following cisplatin treatment in NSCLC cell lines PC9 and A549. Both AURKA inhibition by alisertib and inducible AURKA knockdown potentiated the cytotoxic effects of cisplatin and radiation, leading to tumor regression in doxycycline-inducible xenograft mice. Co-treated cells exhibited increased DNA double-strand breaks, apoptosis, and senescence. Additionally, AURKA inhibition alone by alisertib increased PD-L1 and B7-H3 expression. In conclusion, our study demonstrates that AURKA inhibition enhances the efficacy of platinum-based chemotherapy in NSCLC cells and modulates the expression of multiple immune checkpoints. Therefore, combinatory regimens with AURKA inhibitors should be strategically designed and further studied within the evolving landscape of chemo-immunotherapy.
- Open Access
- 31 May 2023
- Published by Elsevier in Human Pathology Reports
- Vol. 33
Synchronous triple thyroid neoplasms with unique molecular alterations: A rare case report
- 31 May 2023
- Published by Elsevier in Human Pathology Reports
- Vol. 33
Open AccessSynchronous triple thyroid neoplasms with unique molecular alterations: A rare case report
- 19 May 2022
- Published by Wiley in Histopathology
- Vol. 81 (1) , 137-141
Accuracy of risk‐stratifying gastrointestinal stromal tumours using information available during biopsy
- 19 May 2022
- Published by Wiley in Histopathology
- Vol. 81 (1) , 137-141
Accuracy of risk‐stratifying gastrointestinal stromal tumours using information available during biopsy
- 3 September 2021
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 1 (4) , 279-283
Squamous Cell Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland: Unusual Entity and Diagnostic Pitfalls
Background: Carcinoma ex pleomorphic adenoma (PA) of the salivary gland with squamous cell carcinoma (SCC) component is extremely rare and can be easily misdiagnosed as a benign PA or SCC (primary or metastatic). Case Report: A 75-year-old male who had no significant past medical history, presented with a rapid growing right parotid gland mass. A fine needle aspiration revealed malignant cells. Following partial parotidectomy, a 2.4 cm ill-defined mass was grossly identified. Microscopically, it showed a keratinizing SCC with adjacent component of residual PA. Immunohistochemically, the malignant tumor cells were positive for p40, p63 and CK5. The residual PA was focally positive for CAM5.2, SMA, p63 and S100. The pathological features were consistent with SCC ex PA. The patient was well at the 7 month-follow-up post-surgery. Conclusion: SCC ex PA is a rare entity that can be mistaken for a benign PA with squamous metaplasia, or primary or metastatic SCC. It behaves aggressively and has high recurrence and metastasis rate. Awareness of this disease and the diagnostic pitfalls are essential to avoid misinterpretation in difficult cases.
- 3 September 2021
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 1 (4) , 279-283
Squamous Cell Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland: Unusual Entity and Diagnostic Pitfalls
Background: Carcinoma ex pleomorphic adenoma (PA) of the salivary gland with squamous cell carcinoma (SCC) component is extremely rare and can be easily misdiagnosed as a benign PA or SCC (primary or metastatic). Case Report: A 75-year-old male who had no significant past medical history, presented with a rapid growing right parotid gland mass. A fine needle aspiration revealed malignant cells. Following partial parotidectomy, a 2.4 cm ill-defined mass was grossly identified. Microscopically, it showed a keratinizing SCC with adjacent component of residual PA. Immunohistochemically, the malignant tumor cells were positive for p40, p63 and CK5. The residual PA was focally positive for CAM5.2, SMA, p63 and S100. The pathological features were consistent with SCC ex PA. The patient was well at the 7 month-follow-up post-surgery. Conclusion: SCC ex PA is a rare entity that can be mistaken for a benign PA with squamous metaplasia, or primary or metastatic SCC. It behaves aggressively and has high recurrence and metastasis rate. Awareness of this disease and the diagnostic pitfalls are essential to avoid misinterpretation in difficult cases.